Company news
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) news
Every Tenaya Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
June 29, 2026
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in...
June 3, 2026
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wedne...
June 2, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
May 29, 2026
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in...
May 15, 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene...
April 27, 2026
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 11, 2026
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline ...
March 9, 2026
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Ca...
March 5, 2026
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
March 2, 2026
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
January 9, 2026
Tenaya Therapeutics Announces Pricing of Public Offering
December 12, 2025
Tenaya Therapeutics Announces Proposed Public Offering
December 11, 2025
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults w...
December 11, 2025
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
December 11, 2025
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Tre...
November 8, 2025
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American He...
November 4, 2025
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 9, 2025
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
October 2, 2025
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 18, 2025
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
September 2, 2025
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Soc...
August 31, 2025
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 8, 2025
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
July 30, 2025
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
May 13, 2025
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Hea...
April 24, 2025
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American Colleg...
March 31, 2025
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
March 24, 2025
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
March 19, 2025
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
March 3, 2025
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
February 3, 2025
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
January 13, 2025
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hy...
December 17, 2024
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertr...
December 16, 2024
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic...
November 25, 2024
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 6, 2024
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
October 17, 2024
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
September 3, 2024
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 8, 2024
Tenaya Therapeutics Announces Research Leadership Updates
June 27, 2024
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
June 18, 2024
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Ge...
May 2, 2024